{"id": "article-27119_0", "title": "Phenylephrine -- Continuing Education Activity", "content": "Phenylephrine primarily acts as an alpha-1 adrenergic receptor agonist and exhibits\u00a0minimal\u00a0to no beta-adrenergic activity. Consequently,\u00a0the medication\u00a0is an optimal choice for raising mean arterial pressure\u00a0by inducing vasoconstriction in both veins and arteries and enhancing cardiac preload without exerting significant effects on cardiac\u00a0myocytes. The US Food and Drug Administration (FDA) has approved intravenous phenylephrine hydrochloride to elevate blood pressure in adults experiencing clinically significant hypotension, primarily attributed to vasodilation, in situations such as septic shock or anesthesia. Phenylephrine HCL is also an over-the-counter (OTC) medication in ophthalmic formulations to facilitate mydriasis and vasoconstriction of conjunctival blood vessels.\u00a0Furthermore, this medication is administered intranasally\u00a0to treat uncomplicated nasal congestion and is\u00a0an\u00a0OTC additive to topical hemorrhoid medications.", "contents": "Phenylephrine -- Continuing Education Activity. Phenylephrine primarily acts as an alpha-1 adrenergic receptor agonist and exhibits\u00a0minimal\u00a0to no beta-adrenergic activity. Consequently,\u00a0the medication\u00a0is an optimal choice for raising mean arterial pressure\u00a0by inducing vasoconstriction in both veins and arteries and enhancing cardiac preload without exerting significant effects on cardiac\u00a0myocytes. The US Food and Drug Administration (FDA) has approved intravenous phenylephrine hydrochloride to elevate blood pressure in adults experiencing clinically significant hypotension, primarily attributed to vasodilation, in situations such as septic shock or anesthesia. Phenylephrine HCL is also an over-the-counter (OTC) medication in ophthalmic formulations to facilitate mydriasis and vasoconstriction of conjunctival blood vessels.\u00a0Furthermore, this medication is administered intranasally\u00a0to treat uncomplicated nasal congestion and is\u00a0an\u00a0OTC additive to topical hemorrhoid medications."}
{"id": "article-27119_1", "title": "Phenylephrine -- Continuing Education Activity", "content": "This activity provides a comprehensive overview of the indications, mechanism of action, administration methods, adverse event profile, contraindications, monitoring, and toxicity of phenylephrine relevant to the interprofessional healthcare team to effectively guide patient therapy\u00a0in the treatment of diverse conditions for which phenylephrine is indicated.", "contents": "Phenylephrine -- Continuing Education Activity. This activity provides a comprehensive overview of the indications, mechanism of action, administration methods, adverse event profile, contraindications, monitoring, and toxicity of phenylephrine relevant to the interprofessional healthcare team to effectively guide patient therapy\u00a0in the treatment of diverse conditions for which phenylephrine is indicated."}
{"id": "article-27119_2", "title": "Phenylephrine -- Continuing Education Activity", "content": "Objectives: Identify the clinical uses of phenylephrine for the treatment of hypotension caused by vasodilation, such as in septic shock and anesthesia. Assess patient responses to phenylephrine therapy and monitor hemodynamic parameters and adverse events to ensure optimal outcomes and early recognition of complications. Screen patients for contraindications and potential interactions with phenylephrine, particularly in hypersensitivity, bradycardia, severe cardiac dysfunction, and hypovolemia. Collaborate with the interprofessional healthcare team and communicate clearly with pharmacists and nurses to ensure accurate dosing and administration of phenylephrine, thereby improving outcomes and enhancing patient safety. Access free multiple choice questions on this topic.", "contents": "Phenylephrine -- Continuing Education Activity. Objectives: Identify the clinical uses of phenylephrine for the treatment of hypotension caused by vasodilation, such as in septic shock and anesthesia. Assess patient responses to phenylephrine therapy and monitor hemodynamic parameters and adverse events to ensure optimal outcomes and early recognition of complications. Screen patients for contraindications and potential interactions with phenylephrine, particularly in hypersensitivity, bradycardia, severe cardiac dysfunction, and hypovolemia. Collaborate with the interprofessional healthcare team and communicate clearly with pharmacists and nurses to ensure accurate dosing and administration of phenylephrine, thereby improving outcomes and enhancing patient safety. Access free multiple choice questions on this topic."}
{"id": "article-27119_3", "title": "Phenylephrine -- Indications -- FDA-Approved Indications", "content": "The US Food and Drug Administration (FDA) has approved intravenous (IV) phenylephrine hydrochloride to elevate blood pressure in adults experiencing clinically significant hypotension, primarily attributed to vasodilation, in situations such as septic shock or anesthesia. In addition, phenylephrine HCL serves as an over-the-counter (OTC) medication in ophthalmic formulations to facilitate mydriasis and vasoconstriction of conjunctival blood vessels.\u00a0Furthermore, this medication is administered intranasally\u00a0to treat uncomplicated nasal congestion and is\u00a0an\u00a0OTC additive to topical hemorrhoid medications. [1] [2]", "contents": "Phenylephrine -- Indications -- FDA-Approved Indications. The US Food and Drug Administration (FDA) has approved intravenous (IV) phenylephrine hydrochloride to elevate blood pressure in adults experiencing clinically significant hypotension, primarily attributed to vasodilation, in situations such as septic shock or anesthesia. In addition, phenylephrine HCL serves as an over-the-counter (OTC) medication in ophthalmic formulations to facilitate mydriasis and vasoconstriction of conjunctival blood vessels.\u00a0Furthermore, this medication is administered intranasally\u00a0to treat uncomplicated nasal congestion and is\u00a0an\u00a0OTC additive to topical hemorrhoid medications. [1] [2]"}
{"id": "article-27119_4", "title": "Phenylephrine -- Indications -- Off-Label Uses", "content": "Phenylephrine is infrequently utilized off-label as an adjunct to neuraxial or peripheral nerve blockade to treat priapism and other conditions, where the intended outcome is localized vasoconstriction and reduced blood flow.", "contents": "Phenylephrine -- Indications -- Off-Label Uses. Phenylephrine is infrequently utilized off-label as an adjunct to neuraxial or peripheral nerve blockade to treat priapism and other conditions, where the intended outcome is localized vasoconstriction and reduced blood flow."}
{"id": "article-27119_5", "title": "Phenylephrine -- Indications -- Off-Label Uses", "content": "In IV administration, phenylephrine is frequently used as an anesthetic vasopressor for patients exhibiting normal cardiac function and experiencing hypotension due to the vasodilatory effect of anesthetic medications or non-cardiac shock states. The\u00a0American Urological Association (AUA) endorses using intracavernosal phenylephrine to treat\u00a0acute ischemic priapism. [3]", "contents": "Phenylephrine -- Indications -- Off-Label Uses. In IV administration, phenylephrine is frequently used as an anesthetic vasopressor for patients exhibiting normal cardiac function and experiencing hypotension due to the vasodilatory effect of anesthetic medications or non-cardiac shock states. The\u00a0American Urological Association (AUA) endorses using intracavernosal phenylephrine to treat\u00a0acute ischemic priapism. [3]"}
{"id": "article-27119_6", "title": "Phenylephrine -- Indications -- Off-Label Uses", "content": "The FDA has recently stated that utilizing phenylephrine as an oral decongestant is ineffective, even at the standard dosage of 10 mg every 4 hours and at higher doses. Notably, this ruling pertains exclusively to oral formulations and does not encompass nasal phenylephrine or other topical phenylephrine preparations. [4] [ FDA Clarifies Results. 9.14.23 ]", "contents": "Phenylephrine -- Indications -- Off-Label Uses. The FDA has recently stated that utilizing phenylephrine as an oral decongestant is ineffective, even at the standard dosage of 10 mg every 4 hours and at higher doses. Notably, this ruling pertains exclusively to oral formulations and does not encompass nasal phenylephrine or other topical phenylephrine preparations. [4] [ FDA Clarifies Results. 9.14.23 ]"}
{"id": "article-27119_7", "title": "Phenylephrine -- Indications -- Introduction", "content": "Phenylephrine primarily acts as an alpha-1 adrenergic receptor agonist, exhibiting minimal to no beta-adrenergic activity. Consequently, the medication is an optimal choice for raising mean arterial pressure (MAP) by inducing vasoconstriction in both veins and arteries and enhancing cardiac preload without exerting significant effects on cardiac myocytes. [5] Hypotension occurring during general and neuraxial anesthesia continues to be a frequently encountered challenge for anesthesia providers, necessitating swift intervention to avoid prolonged periods of inadequate perfusion. [6]", "contents": "Phenylephrine -- Indications -- Introduction. Phenylephrine primarily acts as an alpha-1 adrenergic receptor agonist, exhibiting minimal to no beta-adrenergic activity. Consequently, the medication is an optimal choice for raising mean arterial pressure (MAP) by inducing vasoconstriction in both veins and arteries and enhancing cardiac preload without exerting significant effects on cardiac myocytes. [5] Hypotension occurring during general and neuraxial anesthesia continues to be a frequently encountered challenge for anesthesia providers, necessitating swift intervention to avoid prolonged periods of inadequate perfusion. [6]"}
{"id": "article-27119_8", "title": "Phenylephrine -- Indications -- Introduction", "content": "A patient's blood pressure may fluctuate significantly throughout a surgical procedure due to various factors, including their underlying medical conditions, the dosage of anesthetic medications, volume status, the degree of surgical stimulation, and concurrent use of other blood pressure\u2013modifying medications. Vasopressor medications, such as phenylephrine, are an excellent option for treating patients with hypotension due to their short onset, brief duration of action, and predictable dose-dependent responses.", "contents": "Phenylephrine -- Indications -- Introduction. A patient's blood pressure may fluctuate significantly throughout a surgical procedure due to various factors, including their underlying medical conditions, the dosage of anesthetic medications, volume status, the degree of surgical stimulation, and concurrent use of other blood pressure\u2013modifying medications. Vasopressor medications, such as phenylephrine, are an excellent option for treating patients with hypotension due to their short onset, brief duration of action, and predictable dose-dependent responses."}
{"id": "article-27119_9", "title": "Phenylephrine -- Indications -- Introduction", "content": "Phenylephrine has emerged as the preferred vasopressor for its effectiveness in counteracting the frequently observed hypotension\u00a0associated with spinal anesthetics (60% to 70%) in obstetric patients. [6] Phenylephrine is also used in the intensive care unit (ICU) environment to treat septic and neurogenic shock. With the advent of\u00a0the Surviving Sepsis Campaign, the management of sepsis has undergone increased scrutiny, leading to the development of a more standardized approach for septic shock states. Norepinephrine is now the preferred vasopressor and inotrope in this context.", "contents": "Phenylephrine -- Indications -- Introduction. Phenylephrine has emerged as the preferred vasopressor for its effectiveness in counteracting the frequently observed hypotension\u00a0associated with spinal anesthetics (60% to 70%) in obstetric patients. [6] Phenylephrine is also used in the intensive care unit (ICU) environment to treat septic and neurogenic shock. With the advent of\u00a0the Surviving Sepsis Campaign, the management of sepsis has undergone increased scrutiny, leading to the development of a more standardized approach for septic shock states. Norepinephrine is now the preferred vasopressor and inotrope in this context."}
{"id": "article-27119_10", "title": "Phenylephrine -- Indications -- Introduction", "content": "Although phenylephrine is not the preferred initial treatment for septic shock, it is an acceptable medication in\u00a0cases of norepinephrine-associated arrhythmias, known high cardiac output with hypotension, and as a salvage therapy when used in combination with inotropic and vasopressor medications, especially when low-dose vasopressin has failed to attain the target MAP. [7] Neurogenic shock resulting from acute traumatic spinal cord injury can also lead to a systemic vasodilatory state, frequently observed alongside preserved cardiac output. In such cases, managing these injuries often necessitates the maintenance of higher target MAPs of typically 85 to 90 mm Hg to\u00a0maintain spinal cord perfusion and reduce secondary injury. Consequently, phenylephrine emerges as a prudent and safe option for maintaining hemodynamic stability in these patients. [8]", "contents": "Phenylephrine -- Indications -- Introduction. Although phenylephrine is not the preferred initial treatment for septic shock, it is an acceptable medication in\u00a0cases of norepinephrine-associated arrhythmias, known high cardiac output with hypotension, and as a salvage therapy when used in combination with inotropic and vasopressor medications, especially when low-dose vasopressin has failed to attain the target MAP. [7] Neurogenic shock resulting from acute traumatic spinal cord injury can also lead to a systemic vasodilatory state, frequently observed alongside preserved cardiac output. In such cases, managing these injuries often necessitates the maintenance of higher target MAPs of typically 85 to 90 mm Hg to\u00a0maintain spinal cord perfusion and reduce secondary injury. Consequently, phenylephrine emerges as a prudent and safe option for maintaining hemodynamic stability in these patients. [8]"}
{"id": "article-27119_11", "title": "Phenylephrine -- Mechanism of Action", "content": "Phenylephrine is a direct-acting sympathomimetic amine that functions as an alpha-1 adrenergic agonist. The drug's chemical structure is closely related to epinephrine and ephedrine, and it exhibits robust vasoconstrictive capabilities when administered via the IV route or applied directly to mucosal membranes. The overall effect of\u00a0IV\u00a0phenylephrine on cardiac output and end-organ perfusion is likely to be more complex and variable based on the dosing method\u2014bolus versus infusion, volume status, baseline heart rate, autonomic tone, and underlying cardiac conditions. These variations are attributable to the degree of\u00a0vasoconstriction, which may result in a temporary increase in preload, arterial constriction leading to heightened systemic vascular resistance and afterload, and reflex bradycardia. These factors collectively contribute to a mixed effect on cardiac output, which can vary depending on the specific patient population. [9] [10] [11] Phenylephrine binds to alpha-1 receptors that innervate the iris dilator muscle, yielding smooth muscle contraction and subsequent pupil dilation during ophthalmic administration. This dilation can aid in fundoscopic exams, improve exposure during specific surgeries, and facilitate the treatment of various medical conditions. [12]", "contents": "Phenylephrine -- Mechanism of Action. Phenylephrine is a direct-acting sympathomimetic amine that functions as an alpha-1 adrenergic agonist. The drug's chemical structure is closely related to epinephrine and ephedrine, and it exhibits robust vasoconstrictive capabilities when administered via the IV route or applied directly to mucosal membranes. The overall effect of\u00a0IV\u00a0phenylephrine on cardiac output and end-organ perfusion is likely to be more complex and variable based on the dosing method\u2014bolus versus infusion, volume status, baseline heart rate, autonomic tone, and underlying cardiac conditions. These variations are attributable to the degree of\u00a0vasoconstriction, which may result in a temporary increase in preload, arterial constriction leading to heightened systemic vascular resistance and afterload, and reflex bradycardia. These factors collectively contribute to a mixed effect on cardiac output, which can vary depending on the specific patient population. [9] [10] [11] Phenylephrine binds to alpha-1 receptors that innervate the iris dilator muscle, yielding smooth muscle contraction and subsequent pupil dilation during ophthalmic administration. This dilation can aid in fundoscopic exams, improve exposure during specific surgeries, and facilitate the treatment of various medical conditions. [12]"}
{"id": "article-27119_12", "title": "Phenylephrine -- Mechanism of Action -- Pharmacokinetics", "content": "Absorption: Phenylephrine's absorption profile differs depending on its route of administration. The ophthalmic application of the medication allows for rapid absorption through the conjunctiva and cornea, resulting in a quick onset of action within minutes. IV administration ensures immediate and complete bioavailability, allowing for rapid systemic distribution.\u00a0Although rectal administration of the medication is somewhat slower than nasal and IV routes, it results in mucosal absorption, with peak concentration typically achieved in approximately 30 to 60 minutes. Nasal delivery facilitates rapid mucosal absorption, achieving peak plasma concentrations within 15 to 30 minutes. [13]", "contents": "Phenylephrine -- Mechanism of Action -- Pharmacokinetics. Absorption: Phenylephrine's absorption profile differs depending on its route of administration. The ophthalmic application of the medication allows for rapid absorption through the conjunctiva and cornea, resulting in a quick onset of action within minutes. IV administration ensures immediate and complete bioavailability, allowing for rapid systemic distribution.\u00a0Although rectal administration of the medication is somewhat slower than nasal and IV routes, it results in mucosal absorption, with peak concentration typically achieved in approximately 30 to 60 minutes. Nasal delivery facilitates rapid mucosal absorption, achieving peak plasma concentrations within 15 to 30 minutes. [13]"}
{"id": "article-27119_13", "title": "Phenylephrine -- Mechanism of Action -- Pharmacokinetics", "content": "Distribution: After absorption, phenylephrine effectively penetrates vascular-rich tissues due to its lipophilic nature, enabling central and peripheral effects. Ophthalmic formulations restrict distribution primarily to ocular compartments, resulting in pupil dilation without significant systemic impact. The steady-state volume of distribution of 340 L surpasses the body's total volume, indicating a substantial volume of distribution.", "contents": "Phenylephrine -- Mechanism of Action -- Pharmacokinetics. Distribution: After absorption, phenylephrine effectively penetrates vascular-rich tissues due to its lipophilic nature, enabling central and peripheral effects. Ophthalmic formulations restrict distribution primarily to ocular compartments, resulting in pupil dilation without significant systemic impact. The steady-state volume of distribution of 340 L surpasses the body's total volume, indicating a substantial volume of distribution."}
{"id": "article-27119_14", "title": "Phenylephrine -- Mechanism of Action -- Pharmacokinetics", "content": "Metabolism: The primary metabolic pathways for phenylephrine include sulfate conjugation, primarily occurring in the intestinal wall, and oxidative deamination catalyzed by monoamine oxidase (MAO)-A and MAO-B enzymes. Glucuronidation also serves as an additional metabolic route for phenylephrine. [13]", "contents": "Phenylephrine -- Mechanism of Action -- Pharmacokinetics. Metabolism: The primary metabolic pathways for phenylephrine include sulfate conjugation, primarily occurring in the intestinal wall, and oxidative deamination catalyzed by monoamine oxidase (MAO)-A and MAO-B enzymes. Glucuronidation also serves as an additional metabolic route for phenylephrine. [13]"}
{"id": "article-27119_15", "title": "Phenylephrine -- Mechanism of Action -- Pharmacokinetics", "content": "Elimination: Renal excretion is the primary elimination pathway for phenylephrine, with most of the drug excreted unchanged in the urine, regardless of whether it was administered nasally, ophthalmically, or rectally. To maintain therapeutic effectiveness, the short half-life of phenylephrine, which is approximately 2.5 to 3 hours, requires frequent dosing intervals, especially when administered via the IV route.", "contents": "Phenylephrine -- Mechanism of Action -- Pharmacokinetics. Elimination: Renal excretion is the primary elimination pathway for phenylephrine, with most of the drug excreted unchanged in the urine, regardless of whether it was administered nasally, ophthalmically, or rectally. To maintain therapeutic effectiveness, the short half-life of phenylephrine, which is approximately 2.5 to 3 hours, requires frequent dosing intervals, especially when administered via the IV route."}
{"id": "article-27119_16", "title": "Phenylephrine -- Administration -- Dosage Forms", "content": "The most common routes of phenylephrine administration include topical, IV, intranasal, ophthalmic, and rectal. Oral formulations should be avoided due to their lack of efficacy.", "contents": "Phenylephrine -- Administration -- Dosage Forms. The most common routes of phenylephrine administration include topical, IV, intranasal, ophthalmic, and rectal. Oral formulations should be avoided due to their lack of efficacy."}
{"id": "article-27119_17", "title": "Phenylephrine -- Administration -- Dosage Forms", "content": "Although less common, phenylephrine has been used as an adjunct to peripheral nerve blockade in the epidural space, intracavernously, via intramuscular injection, and subcutaneously. [14] [15] When administering phenylephrine via the IV route, the usual dosing range is 50 to 100 mcg in aliquots. The drug often necessitates repeated dosing due to its rapid onset of action\u20141 to 3 minutes\u2014and relatively short duration of effect\u20145 to 20 minutes. [16]", "contents": "Phenylephrine -- Administration -- Dosage Forms. Although less common, phenylephrine has been used as an adjunct to peripheral nerve blockade in the epidural space, intracavernously, via intramuscular injection, and subcutaneously. [14] [15] When administering phenylephrine via the IV route, the usual dosing range is 50 to 100 mcg in aliquots. The drug often necessitates repeated dosing due to its rapid onset of action\u20141 to 3 minutes\u2014and relatively short duration of effect\u20145 to 20 minutes. [16]"}
{"id": "article-27119_18", "title": "Phenylephrine -- Administration -- Adult Dosage", "content": "Phenylephrine can be administered to patients through weight-based or non-weight\u2013based infusions. Dosages usually range from 0.1 to 1.5 mcg/kg/min. [17] Contrary to the conventional teaching that all vasoactive drugs should be administered through central venous access to prevent tissue necrosis in case of extravasation, phenylephrine has proven safe and efficacious when administered via peripheral IV catheters.\u00a0This is achievable through proper dilution, appropriate vein and catheter selection, and\u00a0frequent site inspection. [18]", "contents": "Phenylephrine -- Administration -- Adult Dosage. Phenylephrine can be administered to patients through weight-based or non-weight\u2013based infusions. Dosages usually range from 0.1 to 1.5 mcg/kg/min. [17] Contrary to the conventional teaching that all vasoactive drugs should be administered through central venous access to prevent tissue necrosis in case of extravasation, phenylephrine has proven safe and efficacious when administered via peripheral IV catheters.\u00a0This is achievable through proper dilution, appropriate vein and catheter selection, and\u00a0frequent site inspection. [18]"}
{"id": "article-27119_19", "title": "Phenylephrine -- Administration -- Strengths", "content": "Ophthalmic solutions of phenylephrine offer a diverse array of concentrations and additives tailored to achieve specific effects. Medical practitioners commonly use these concentrations that are available in strengths of 1%, 2.5%, or 10%. The 1% formulations are frequently combined with 0.2% cyclopentolate for dilated fundus and cycloplegic examinations in newborns younger than 3 months. The 2.5% formulations are the preferred choice for dilated fundus examinations in adults and children older than 3 months and as an aid for diagnosing episcleritis. Although the 10% formulation is less frequently used\u00a0primarily due to concerns regarding systemic absorption, it may be used for dilated examinations and to\u00a0provide exposure during surgical procedures.", "contents": "Phenylephrine -- Administration -- Strengths. Ophthalmic solutions of phenylephrine offer a diverse array of concentrations and additives tailored to achieve specific effects. Medical practitioners commonly use these concentrations that are available in strengths of 1%, 2.5%, or 10%. The 1% formulations are frequently combined with 0.2% cyclopentolate for dilated fundus and cycloplegic examinations in newborns younger than 3 months. The 2.5% formulations are the preferred choice for dilated fundus examinations in adults and children older than 3 months and as an aid for diagnosing episcleritis. Although the 10% formulation is less frequently used\u00a0primarily due to concerns regarding systemic absorption, it may be used for dilated examinations and to\u00a0provide exposure during surgical procedures."}
{"id": "article-27119_20", "title": "Phenylephrine -- Administration -- Strengths", "content": "OTC phenylephrine combination drops can be found in concentrations as low as 0.12% and are often marketed for red-eye relief or the treatment of uncomplicated conjunctivitis. In addition, phenylephrine is available as an FDA-approved nasal solution, typically ranging from 0.125% to 1%. [19] [20]", "contents": "Phenylephrine -- Administration -- Strengths. OTC phenylephrine combination drops can be found in concentrations as low as 0.12% and are often marketed for red-eye relief or the treatment of uncomplicated conjunctivitis. In addition, phenylephrine is available as an FDA-approved nasal solution, typically ranging from 0.125% to 1%. [19] [20]"}
{"id": "article-27119_21", "title": "Phenylephrine -- Administration -- Specific Patient Populations", "content": "Hepatic impairment: In\u00a0cases of liver impairment, caution is warranted when dosing phenylephrine, as the liver plays a pivotal role in synthesizing essential factors contributing to blood pressure regulation. These include clotting factors, angiotensinogen, nitric oxide, and vasoactive substances. Alterations\u00a0in drug metabolism and reduced clearance in cases of hepatic impairment may necessitate dosage adjustments. To ensure the safe and effective use of phenylephrine in individuals with liver impairment, it is often necessary to implement individualized dosing, which may involve larger than standard doses, along with vigilant monitoring.", "contents": "Phenylephrine -- Administration -- Specific Patient Populations. Hepatic impairment: In\u00a0cases of liver impairment, caution is warranted when dosing phenylephrine, as the liver plays a pivotal role in synthesizing essential factors contributing to blood pressure regulation. These include clotting factors, angiotensinogen, nitric oxide, and vasoactive substances. Alterations\u00a0in drug metabolism and reduced clearance in cases of hepatic impairment may necessitate dosage adjustments. To ensure the safe and effective use of phenylephrine in individuals with liver impairment, it is often necessary to implement individualized dosing, which may involve larger than standard doses, along with vigilant monitoring."}
{"id": "article-27119_22", "title": "Phenylephrine -- Administration -- Specific Patient Populations", "content": "Renal impairment: Patients with end-stage renal disease undergoing hemodialysis tend to exhibit heightened sensitivity to phenylephrine, as dose-response data indicates. Therefore, it is advisable to consider administering lower doses of IV phenylephrine in patients with renal impairment.", "contents": "Phenylephrine -- Administration -- Specific Patient Populations. Renal impairment: Patients with end-stage renal disease undergoing hemodialysis tend to exhibit heightened sensitivity to phenylephrine, as dose-response data indicates. Therefore, it is advisable to consider administering lower doses of IV phenylephrine in patients with renal impairment."}
{"id": "article-27119_23", "title": "Phenylephrine -- Administration -- Specific Patient Populations", "content": "Pregnancy considerations: According to the American Society of Anesthesiology guidelines, IV ephedrine and phenylephrine are suitable options for managing hypotension resulting from neuraxial anesthesia during pregnancy. In cases where maternal bradycardia is not a concern, phenylephrine may be preferred due to its potential to improve fetal acid-base balance in uncomplicated pregnancies. [21]", "contents": "Phenylephrine -- Administration -- Specific Patient Populations. Pregnancy considerations: According to the American Society of Anesthesiology guidelines, IV ephedrine and phenylephrine are suitable options for managing hypotension resulting from neuraxial anesthesia during pregnancy. In cases where maternal bradycardia is not a concern, phenylephrine may be preferred due to its potential to improve fetal acid-base balance in uncomplicated pregnancies. [21]"}
{"id": "article-27119_24", "title": "Phenylephrine -- Administration -- Specific Patient Populations", "content": "Breastfeeding considerations: The systemic administration of phenylephrine may potentially reduce milk production. Due to the absence of breastfeeding safety data for oral phenylephrine, it is prudent to explore alternative options, particularly when nursing a newborn or preterm infant. Using phenylephrine through nasal spray or ophthalmic drops is less likely to have a negative impact on lactation for breastfeeding individuals. To minimize the drug's effects after eye drop application, it is advisable to apply pressure near the tear duct for at least 1 minute and subsequently remove any excess solution using an absorbent tissue. [22] Pediatric patients: The safety and effectiveness of IV phenylephrine in pediatric patients have not been established.", "contents": "Phenylephrine -- Administration -- Specific Patient Populations. Breastfeeding considerations: The systemic administration of phenylephrine may potentially reduce milk production. Due to the absence of breastfeeding safety data for oral phenylephrine, it is prudent to explore alternative options, particularly when nursing a newborn or preterm infant. Using phenylephrine through nasal spray or ophthalmic drops is less likely to have a negative impact on lactation for breastfeeding individuals. To minimize the drug's effects after eye drop application, it is advisable to apply pressure near the tear duct for at least 1 minute and subsequently remove any excess solution using an absorbent tissue. [22] Pediatric patients: The safety and effectiveness of IV phenylephrine in pediatric patients have not been established."}
{"id": "article-27119_25", "title": "Phenylephrine -- Administration -- Specific Patient Populations", "content": "Older patients: The limited data on phenylephrine's effectiveness in individuals 65 and older warrant careful consideration when selecting doses. Phenylephrine should be initiated at the lower end of the dosage spectrum, considering the potential for age-related hepatic, renal, and cardiac impairment and polypharmacy-related factors.", "contents": "Phenylephrine -- Administration -- Specific Patient Populations. Older patients: The limited data on phenylephrine's effectiveness in individuals 65 and older warrant careful consideration when selecting doses. Phenylephrine should be initiated at the lower end of the dosage spectrum, considering the potential for age-related hepatic, renal, and cardiac impairment and polypharmacy-related factors."}
{"id": "article-27119_26", "title": "Phenylephrine -- Adverse Effects", "content": "The most frequently reported adverse reactions of phenylephrine comprise nausea, vomiting, headache, and nervousness in patients while awake. Due to its selective alpha-receptor stimulation, phenylephrine can induce baroreceptor-mediated reflex bradycardia. In cases of bradycardia and hypotension, healthcare providers should contemplate various classes of vasopressor medications. In specific patient populations, primarily hypovolemic patients with cardiac dysfunction, phenylephrine has the potential to elevate afterload more than preload, leading to reduced cardiac output and potentially worsening conditions such as angina, heart failure, and pulmonary hypertension. [9]", "contents": "Phenylephrine -- Adverse Effects. The most frequently reported adverse reactions of phenylephrine comprise nausea, vomiting, headache, and nervousness in patients while awake. Due to its selective alpha-receptor stimulation, phenylephrine can induce baroreceptor-mediated reflex bradycardia. In cases of bradycardia and hypotension, healthcare providers should contemplate various classes of vasopressor medications. In specific patient populations, primarily hypovolemic patients with cardiac dysfunction, phenylephrine has the potential to elevate afterload more than preload, leading to reduced cardiac output and potentially worsening conditions such as angina, heart failure, and pulmonary hypertension. [9]"}
{"id": "article-27119_27", "title": "Phenylephrine -- Adverse Effects -- Drug-Drug Interactions", "content": "The medications listed below effectively increase the pressor effect of phenylephrine.", "contents": "Phenylephrine -- Adverse Effects -- Drug-Drug Interactions. The medications listed below effectively increase the pressor effect of phenylephrine."}
{"id": "article-27119_28", "title": "Phenylephrine -- Adverse Effects -- Drug-Drug Interactions", "content": "Propranolol: This drug is a nonselective beta-adrenergic antagonist that enhances the vasoconstrictive effects of phenylephrine by inhibiting the influence of sympathetic stimulation on the heart and blood vessels. Clonidine: This drug is an alpha-2 adrenergic agonist that suppresses sympathetic outflow from the central nervous system, thereby increasing sensitivity to vasoconstrictors such as phenylephrine. Amitriptyline: This drug is a tricyclic antidepressant that extends the action of endogenous norepinephrine by inhibiting its reuptake, thereby enhancing phenylephrine's effects. Atomoxetine: This drug is\u00a0a norepinephrine reuptake inhibitor that increases the availability of norepinephrine, thereby enhancing the pressor effect of phenylephrine. Prednisone: This drug and other steroids sensitize vasculature to catecholamines, such as phenylephrine, thereby augmenting\u00a0their vasoconstrictive action.", "contents": "Phenylephrine -- Adverse Effects -- Drug-Drug Interactions. Propranolol: This drug is a nonselective beta-adrenergic antagonist that enhances the vasoconstrictive effects of phenylephrine by inhibiting the influence of sympathetic stimulation on the heart and blood vessels. Clonidine: This drug is an alpha-2 adrenergic agonist that suppresses sympathetic outflow from the central nervous system, thereby increasing sensitivity to vasoconstrictors such as phenylephrine. Amitriptyline: This drug is a tricyclic antidepressant that extends the action of endogenous norepinephrine by inhibiting its reuptake, thereby enhancing phenylephrine's effects. Atomoxetine: This drug is\u00a0a norepinephrine reuptake inhibitor that increases the availability of norepinephrine, thereby enhancing the pressor effect of phenylephrine. Prednisone: This drug and other steroids sensitize vasculature to catecholamines, such as phenylephrine, thereby augmenting\u00a0their vasoconstrictive action."}
{"id": "article-27119_29", "title": "Phenylephrine -- Adverse Effects -- Drug-Drug Interactions", "content": "Ergot alkaloids: These\u00a0drugs possess vasoconstrictor properties, and when used in conjunction with phenylephrine, they produce additive or synergistic effects on blood pressure. [23] MAO inhibitors: These inhibitors increase the availability of norepinephrine, thereby potentiating phenylephrine's pressor response. [24] The\u00a0medications listed below effectively decrease the pressor effect of phenylephrine.", "contents": "Phenylephrine -- Adverse Effects -- Drug-Drug Interactions. Ergot alkaloids: These\u00a0drugs possess vasoconstrictor properties, and when used in conjunction with phenylephrine, they produce additive or synergistic effects on blood pressure. [23] MAO inhibitors: These inhibitors increase the availability of norepinephrine, thereby potentiating phenylephrine's pressor response. [24] The\u00a0medications listed below effectively decrease the pressor effect of phenylephrine."}
{"id": "article-27119_30", "title": "Phenylephrine -- Adverse Effects -- Drug-Drug Interactions", "content": "Phenothiazines, such as chlorpromazine: Phenothiazines are known for their primary antipsychotic property, and they exhibit alpha-1 adrenergic antagonist activity. This secondary characteristic reduces phenylephrine's pressor effect by obstructing the vasoconstrictive actions mediated through alpha-1 receptors. Alpha-1 adrenergic antagonists: These antagonists directly inhibit the alpha-1 receptors on smooth muscle, counteracting the vasoconstrictive effects of phenylephrine. [25]", "contents": "Phenylephrine -- Adverse Effects -- Drug-Drug Interactions. Phenothiazines, such as chlorpromazine: Phenothiazines are known for their primary antipsychotic property, and they exhibit alpha-1 adrenergic antagonist activity. This secondary characteristic reduces phenylephrine's pressor effect by obstructing the vasoconstrictive actions mediated through alpha-1 receptors. Alpha-1 adrenergic antagonists: These antagonists directly inhibit the alpha-1 receptors on smooth muscle, counteracting the vasoconstrictive effects of phenylephrine. [25]"}
{"id": "article-27119_31", "title": "Phenylephrine -- Contraindications", "content": "There are no definitive contraindications to phenylephrine except hypersensitivity to the drug or its components. [26] IV phenylephrine contains sodium metabisulfite, which can induce allergic reactions, including anaphylactic symptoms or less severe asthmatic episodes in susceptible individuals. [27] The exact prevalence of sulfite sensitivity remains unclear but is likely low.", "contents": "Phenylephrine -- Contraindications. There are no definitive contraindications to phenylephrine except hypersensitivity to the drug or its components. [26] IV phenylephrine contains sodium metabisulfite, which can induce allergic reactions, including anaphylactic symptoms or less severe asthmatic episodes in susceptible individuals. [27] The exact prevalence of sulfite sensitivity remains unclear but is likely low."}
{"id": "article-27119_32", "title": "Phenylephrine -- Contraindications -- Warning and Precautions", "content": "Phenylephrine use warrants caution in patients with a history of bradycardia, severe cardiac dysfunction, and hypovolemia. IV phenylephrine may worsen angina, heart failure, or pulmonary arterial hypertension in patients with severe arteriosclerosis or a history of angina. Individuals with autonomic dysfunction, possibly resulting from spinal cord injuries, may experience an increased pressure response to adrenergic drugs such as phenylephrine. The extravasation of phenylephrine can lead to tissue necrosis or sloughing. [28] The concurrent use of sympathomimetic drugs can intensify the pressor effect of phenylephrine, potentially increasing the risk of hemorrhagic stroke. [29]", "contents": "Phenylephrine -- Contraindications -- Warning and Precautions. Phenylephrine use warrants caution in patients with a history of bradycardia, severe cardiac dysfunction, and hypovolemia. IV phenylephrine may worsen angina, heart failure, or pulmonary arterial hypertension in patients with severe arteriosclerosis or a history of angina. Individuals with autonomic dysfunction, possibly resulting from spinal cord injuries, may experience an increased pressure response to adrenergic drugs such as phenylephrine. The extravasation of phenylephrine can lead to tissue necrosis or sloughing. [28] The concurrent use of sympathomimetic drugs can intensify the pressor effect of phenylephrine, potentially increasing the risk of hemorrhagic stroke. [29]"}
{"id": "article-27119_33", "title": "Phenylephrine -- Monitoring", "content": "Currently, no specific protocols exist for monitoring the use of IV phenylephrine. However, vasoactive medications should only be administered within perioperative or ICU settings or in situations where monitoring of heart rate, rhythm, blood pressure, and pulse oximetry is accessible. Although\u00a0many traditional texts recommend administering all vasoactive medications via a central line, it is common practice to administer phenylephrine peripherally in the operative setting. This approach has been proven safe, even during prolonged infusions through 18- to 20-gauge IV catheters placed in large veins, provided frequent site inspections are conducted. [18]", "contents": "Phenylephrine -- Monitoring. Currently, no specific protocols exist for monitoring the use of IV phenylephrine. However, vasoactive medications should only be administered within perioperative or ICU settings or in situations where monitoring of heart rate, rhythm, blood pressure, and pulse oximetry is accessible. Although\u00a0many traditional texts recommend administering all vasoactive medications via a central line, it is common practice to administer phenylephrine peripherally in the operative setting. This approach has been proven safe, even during prolonged infusions through 18- to 20-gauge IV catheters placed in large veins, provided frequent site inspections are conducted. [18]"}
{"id": "article-27119_34", "title": "Phenylephrine -- Monitoring", "content": "Despite the prevalent practice of administering IV phenylephrine peripherally, a systematic review of published articles concerning the peripheral administration of vasoactive medications and reports of extravasation revealed only 2 instances of skin necrosis. These cases occurred in high-risk patients receiving peripherally administered phenylephrine. [30] Administering phenylephrine through central venous catheters, whenever feasible, or the most prominent proximal vein available is recommended. Regular inspections and blood aspiration should be conducted.", "contents": "Phenylephrine -- Monitoring. Despite the prevalent practice of administering IV phenylephrine peripherally, a systematic review of published articles concerning the peripheral administration of vasoactive medications and reports of extravasation revealed only 2 instances of skin necrosis. These cases occurred in high-risk patients receiving peripherally administered phenylephrine. [30] Administering phenylephrine through central venous catheters, whenever feasible, or the most prominent proximal vein available is recommended. Regular inspections and blood aspiration should be conducted."}
{"id": "article-27119_35", "title": "Phenylephrine -- Monitoring", "content": "Topical, ophthalmic, and nasal administrations of phenylephrine are generally well-tolerated, although there is always a potential concern for systemic absorption. Although there have been reports of hemodynamic instability associated with administering higher concentrations (10%) of ophthalmic phenylephrine, using lesser concentrations (2.5%) has resulted in no statistically significant difference in heart rate or blood pressure. [31] There\u00a0seems to be no significant impact on hemodynamics when\u00a0phenylephrine is administered at standard dosages. [19] [32] [33] [34] [35]", "contents": "Phenylephrine -- Monitoring. Topical, ophthalmic, and nasal administrations of phenylephrine are generally well-tolerated, although there is always a potential concern for systemic absorption. Although there have been reports of hemodynamic instability associated with administering higher concentrations (10%) of ophthalmic phenylephrine, using lesser concentrations (2.5%) has resulted in no statistically significant difference in heart rate or blood pressure. [31] There\u00a0seems to be no significant impact on hemodynamics when\u00a0phenylephrine is administered at standard dosages. [19] [32] [33] [34] [35]"}
{"id": "article-27119_36", "title": "Phenylephrine -- Toxicity", "content": "Currently, there is no known antidote for IV phenylephrine. Hypertension resulting from excessive dosing or an exaggerated response is typically transient, primarily due to the short duration of action. The treatment for hypertension or symptomatic reflex bradycardia involves discontinuing the administration of phenylephrine and administering chronotropic agents or vasodilators as necessary. The treatment for tissue extravasation resulting from peripherally administered phenylephrine primarily involves supportive care, including fluid aspiration, warming, and elevation. In some cases, subcutaneous phentolamine can also be considered. [36]", "contents": "Phenylephrine -- Toxicity. Currently, there is no known antidote for IV phenylephrine. Hypertension resulting from excessive dosing or an exaggerated response is typically transient, primarily due to the short duration of action. The treatment for hypertension or symptomatic reflex bradycardia involves discontinuing the administration of phenylephrine and administering chronotropic agents or vasodilators as necessary. The treatment for tissue extravasation resulting from peripherally administered phenylephrine primarily involves supportive care, including fluid aspiration, warming, and elevation. In some cases, subcutaneous phentolamine can also be considered. [36]"}
{"id": "article-27119_37", "title": "Phenylephrine -- Enhancing Healthcare Team Outcomes", "content": "Phenylephrine is frequently administered in diverse hospital settings, including the ICU, operating room, labor and delivery, and emergency department. The dilution\u00a0and administration of the medication may necessitate the involvement of multiple healthcare providers, such as pharmacists, nurses, advanced care practitioners, certified registered nurse anesthetists, and physicians.", "contents": "Phenylephrine -- Enhancing Healthcare Team Outcomes. Phenylephrine is frequently administered in diverse hospital settings, including the ICU, operating room, labor and delivery, and emergency department. The dilution\u00a0and administration of the medication may necessitate the involvement of multiple healthcare providers, such as pharmacists, nurses, advanced care practitioners, certified registered nurse anesthetists, and physicians."}
{"id": "article-27119_38", "title": "Phenylephrine -- Enhancing Healthcare Team Outcomes", "content": "Manufacturers typically supply IV phenylephrine in highly concentrated 10 mg/mL doses, necessitating dilution before administration. Phenylephrine is often linked to medication errors and can contribute to up to 10% of all errors in the perioperative setting. For this reason, it is crucial for pharmacists and nurses, in particular, to maintain clear communication among patients and healthcare providers to guarantee accurate dosing and administration.", "contents": "Phenylephrine -- Enhancing Healthcare Team Outcomes. Manufacturers typically supply IV phenylephrine in highly concentrated 10 mg/mL doses, necessitating dilution before administration. Phenylephrine is often linked to medication errors and can contribute to up to 10% of all errors in the perioperative setting. For this reason, it is crucial for pharmacists and nurses, in particular, to maintain clear communication among patients and healthcare providers to guarantee accurate dosing and administration."}
{"id": "article-27119_39", "title": "Phenylephrine -- Enhancing Healthcare Team Outcomes", "content": "All healthcare providers responsible for administering phenylephrine to patients should acquaint themselves with the correct dilution procedures. [37] According to the manufacturer's guidelines for bolus dosing, 10 mg of phenylephrine should be mixed with 99 mL of 5% dextrose or 0.9% sodium chloride solutions, resulting in a 100 mcg/mL concentration. For continuous infusions, the recommendation is that 10 mg of phenylephrine be added to 500 mL of 5% dextrose or 0.9% sodium chloride solutions, yielding a 20 mcg/mL concentration.", "contents": "Phenylephrine -- Enhancing Healthcare Team Outcomes. All healthcare providers responsible for administering phenylephrine to patients should acquaint themselves with the correct dilution procedures. [37] According to the manufacturer's guidelines for bolus dosing, 10 mg of phenylephrine should be mixed with 99 mL of 5% dextrose or 0.9% sodium chloride solutions, resulting in a 100 mcg/mL concentration. For continuous infusions, the recommendation is that 10 mg of phenylephrine be added to 500 mL of 5% dextrose or 0.9% sodium chloride solutions, yielding a 20 mcg/mL concentration."}
{"id": "article-27119_40", "title": "Phenylephrine -- Enhancing Healthcare Team Outcomes", "content": "When\u00a0both pharmacists and nurses are familiar with the correct dosing and dilution of the medication, they can act as a dual safety check alongside the physician to confirm the appropriateness of dosing. Communication channels should allow them to communicate their concerns with the ordering physician promptly.", "contents": "Phenylephrine -- Enhancing Healthcare Team Outcomes. When\u00a0both pharmacists and nurses are familiar with the correct dosing and dilution of the medication, they can act as a dual safety check alongside the physician to confirm the appropriateness of dosing. Communication channels should allow them to communicate their concerns with the ordering physician promptly."}
{"id": "article-27119_41", "title": "Phenylephrine -- Enhancing Healthcare Team Outcomes", "content": "Notably, the\u00a0Rapid Response and Code teams are composed of members with varying levels of education and experience, even though they may reduce morbidity and mortality. [38] [39] As phenylephrine may be the preferred vasopressor in numerous emergency situations, any potential code team leader should be familiar with and rehearse the direction of its administration. The use of specific closed-loop communications, such as \"Please dilute a 10-mg vial of phenylephrine in a 100-mL bag of normal saline and administer 2 mL of 100 mcg/mL through the patient's central line, and inform me when it has been given,\" as opposed to general instructions, such as \"Please give the patient 200 mcg of phenylephrine,\" has been demonstrated not only to decrease medication errors but also to improve the speed of task completion during emergencies significantly. [40] This information is derived from a prospective observational study with intervention-level II evidence as its foundation.", "contents": "Phenylephrine -- Enhancing Healthcare Team Outcomes. Notably, the\u00a0Rapid Response and Code teams are composed of members with varying levels of education and experience, even though they may reduce morbidity and mortality. [38] [39] As phenylephrine may be the preferred vasopressor in numerous emergency situations, any potential code team leader should be familiar with and rehearse the direction of its administration. The use of specific closed-loop communications, such as \"Please dilute a 10-mg vial of phenylephrine in a 100-mL bag of normal saline and administer 2 mL of 100 mcg/mL through the patient's central line, and inform me when it has been given,\" as opposed to general instructions, such as \"Please give the patient 200 mcg of phenylephrine,\" has been demonstrated not only to decrease medication errors but also to improve the speed of task completion during emergencies significantly. [40] This information is derived from a prospective observational study with intervention-level II evidence as its foundation."}
{"id": "article-27119_42", "title": "Phenylephrine -- Enhancing Healthcare Team Outcomes", "content": "This study underscores the significance of a collaborative interprofessional team approach in optimizing therapy with phenylephrine and mitigating medication errors. Healthcare professionals, including clinicians, pharmacists, and nurses, should prioritize patient education. Patients should be informed that oral OTC phenylephrine-containing products are not recommended. However, other topical formulations of phenylephrine may be utilized for approved indications.", "contents": "Phenylephrine -- Enhancing Healthcare Team Outcomes. This study underscores the significance of a collaborative interprofessional team approach in optimizing therapy with phenylephrine and mitigating medication errors. Healthcare professionals, including clinicians, pharmacists, and nurses, should prioritize patient education. Patients should be informed that oral OTC phenylephrine-containing products are not recommended. However, other topical formulations of phenylephrine may be utilized for approved indications."}
{"id": "article-27119_43", "title": "Phenylephrine -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Phenylephrine -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}